Depemokimab cuts exacerbation rate in eosinophilic asthma
For patients with severe asthma with an eosinophilic phenotype, depemokimab reduces the annualized rate of exacerbations, according to a study published online Sept. 9 in the New England Journal of Medicine to coincide with ...
15 hours ago
0
0